Abstract: Disclosed is a method for preparing a product for treating scald infection caused by Pseudomonas aeruginosa. The product includes a ferrous sulfate hydrogel, the scald is a deep second-degree scald or a third-degree scald, and a preparation process of the ferrous sulfate hydrogel includes: S1, obtaining a mixed solution by dissolving ferrous sulfate and vitamin C at a concentration ratio of 1:1 in sterile ultrapure water, heating the mixed solution to 50° C., and a concentration of the ferrous sulfate in the mixed solution being 2 mM, and S2, under a condition of heating, continuing to add sodium alginate powder whose mass constitutes 3.5% of a total mass of the mixed solution, stirring until the sodium alginate powder is dissolved and forming a stable colloid, and obtaining 2 mM of the ferrous sulfate hydrogel.

Abstract: Compositions are provided that comprise a microvesicle derived from an edible plant. The microvesicles are coated with a plasma membrane derived from a targeting cell and can further be utilized to encapsulate a therapeutic agent. Methods for treating an inflammatory disorder and/or a cancer are further provided and include the step of administering to a subject an effective amount of a composition that includes a microvesicle coated with a plasma membrane derived from a targeting cell.

Abstract: The present invention provides a method of preparing a lipid nanoparticle dispersion using a twin screw extruder. The inventive DNLF fluids are isotropic fluids which include greater than 25% lipophilic content in the form of lipidic nanoparticles dispersed in a continuous aqueous matrix with turbidity less than 375 nephelometric turbidity units (NTU).

Abstract: A method for the preparation of a composition includes dispersing particulate pimobendan in a molten carrier matrix to form particles coated with the carrier matrix, where the molten carrier matrix includes one or more pharmaceutically acceptable carriers selected from a polyglycolized glyceride, a polyethylene glycol, and combinations thereof, atomizing the dispersion of coated particles, and cooling and collecting the coated particles from the atomized dispersion.

Abstract: This disclosure is directed to a composition that includes Citrus sinensis, Blood Orange; Daucus carota, Carrot; Beta vulgaris, Beet; Curcuma longa, Turmeric; Bixa orellana, Annatto; Rosmarinus officinalis, Rosemary; Saccharina latissima, Kombu; Polypodium leucotomos; Nicotinamide Adenine Dinucleotide, and an oil; and includes methods of making the composition; and methods of using the composition for sunless tanning.

Abstract: A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.

Abstract: The present invention relates to an aqueous composition comprising an aqueous solution, ?-TCP, a silicate compound and a phosphorylated amino acid. The composition has improved mechanical strength and is easily applied and may be used as a tissue adhesive, implant or a filler.

Abstract: The invention described herein includes a self-neutralizing amino acid-based cationic composition that contains an amino acid-based cationic ester, a nonionic amphiphile, and an anhydrous buffering agent. In an embodiment, the composition, when dispersed or dissolved in an aqueous solvent, provides a resultant solution/dispersion having a pH of greater than about 4. The amino acid-based cationic ester may be a reaction product of (i) an amino acid having a non-polar side chain, and an amine group that has been neutralized with an acid; with (ii) a long chain fatty alcohol. Also included within the scope of the invention are methods of preparing a self-neutralizing amino acid-based cationic composition, such method including combining an amino acid-based cationic ester, a nonionic amphiphile and an anhydrous buffering agent. The resulting composition is in an anhydrous solid form. Formulations containing the amino acid-based cationic ester and/or a composition that includes it, are also disclosed.

Abstract: A pharmaceutical composition for use in the treatment of the symptoms of an addiction is disclosed. The pharmaceutical composition contains, but is not limited to, digestive enzymes. The pharmaceutical composition may further contain a coating that surrounds a core of digestive enzymes in the form of coated particles. The pharmaceutical composition may also be encapsulated. The therapeutic agent may be manufactured by a variety of technologies.

Abstract: The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).

Abstract: Hydrophilic molecules such as biologics, which can include peptides, proteins, and other biologically-derived materials, can be used as therapeutic agents in medical applications. They can face administration challenges because of poor membrane permeability and rapid clearance from the blood stream. Methods for the formation of a core-shell-brush nanoparticle from an A-B-C triblock copolymer are set forth. A hydrophilic core can contain the biologic and the C Block of the copolymer. The shell can be comprised of the precipitated B Block, and the A Block can form a stabilizing brush layer. The particles can be assembled by sequential precipitations under defined mixing conditions. Presented herein are methods to tune release based on process parameters during particle assembly and triblock characteristics.

Abstract: In an aspect of the present invention, a fluoropolymer represented by formula 1 is provided. The fluoropolymer provided in one aspect of the present invention can obtain low surface energy and high light transmittance, and thus can be applied to various applications requiring such properties. In particular, when the fluoropolymer is coated on glass, the surface energy can be lowered to 19 mN/m or less and the light transmittance can be increased by 2% or more. At the same time, it has the effect of exhibiting excellent pencil hardness. In addition, the fluoropolymer provided in one aspect of the present invention can be applied as a surface coating and membrane material of various products due to its high solubility in general organic solvents, despite having very low surface energy during coating.

Abstract: The present disclosure provides for a hydrogel formulation comprising a therapeutically effective amount of an extract of the Croton lechleri tree. The present disclosure also provides for a method of treating a dermatological condition in a subject via the topical administration of a hydrogel formulation comprising a therapeutically effective amount of an extract of the Croton lechleri tree.

Abstract: A compound according to Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 and R2 are each independently selected from optionally substituted C1-6-alkyl and optionally substituted aryl; R3, R4, R5, and R6 are each independently selected from the group consisting of H, halo, optionally substituted C1-6-alkyl, and optionally substituted C1-6 alkoxy; and R7 is a phosphorus containing moiety, wherein a phosphorus atom is bonded to Au.

Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

Abstract: The invention relates to a stable, peroxide-free pharmaceutical composition of 8-chloro-5-methyl-1-[4-(2-pyridyloxy)cyclohexyl]-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, and a process for the preparation thereof and its use in the treatment of diseases or conditions in which V1a inhibition plays a role or is implicated, such as autism spectrum disorder (ASD), and the core social and communication deficits of patients associated therewith. The formulation includes a compressed tablet kernel comprising: (a) compound of formula I, disintegrant, filler, glidant and lubricant; and (b) a film coating system comprising coating agent, colorant, plasticizer, anti-tacking agent, and coating vehicle. The process for making the formulation comprises combining the tablet kernel ingredients into a blend, sieving the blend, and compressing the blend to form a tablet kernel, and spraying the film coating system onto the tablet kernels.

Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.

Abstract: A dental desensitizer, including, by weight: 1-20 parts of a protein modified by polyethylene glycol; 1-10 parts of tris(2-carboxyethyl) phosphine hydrochloride; 1-3 parts of calcium chloride; and 2-20 parts of a pH regulator.

Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in poultry which have been subject to overfeeding. Feeds containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.

Abstract: The present invention relates to improved formulations of propandiol mononitrate and derivatives thereof as well as to the production of such formulations.